Publications list Including posters, presentations, and conference abstracts September 2021 Xcenda Page 1 of 86 PUBLICATIONS Go to Posters Publication links by year: 2020 2021 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 1990s 2021 ∗Ananthasubramaniam K, Kitt TM, Saxena A, Feng Q, Nimke D, Spalding JR, Xu Y. Healthcare resource utilization among patients receiving non-invasive testing for coronary artery disease in an outpatient setting: a cohort study reflecting daily practice trends. J Nucl Cardiol. 2021 Mar 3 [published online ahead of print]. doi:10.1007/s12350-021-02549-2 Arnaud A, Suthoff E, Stenson K, Werneburg B, Hodgkins P, Bonthapally V, Jonas J, Meyer K, O’Day K. Number needed to treat and number needed to harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder. J Affect Disord. 2021 April;285:112-119. Bensink M, Shah S, Shah N, Desai P, Khan F, Rubin A, Ailani J, Dougherty C, McLeod K, Quillen A. Tracking migraine digitally: The future of migraine management. J Nurse Pract. 2021;17(4):462. Davies F, Rifkin R, Castello C, Morgan G, Usami S, Abonour F, Palumbo A, Romanus D, Hajek R, Terpos E, Cherepanov D, Stull DM, Huang H, Leleu X, Berdeja J, Lee HC, Weisel K, Thompson M, Boccadoro M, Zonder J, Cook G, Puig N, Vela-Ojeda J, Farrelly E, Raju A, Blazer M, Chari A. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. Ann Hematol. 2021. May 10 [published online ahead of print]. doi:10.1007/s00277-021-04534-8 Laurenz M, von Eiff C, Borchert K, Jacob C, Seidel K, Schley K. Vaccination rates and adherence in pneumococcal conjugate vaccination in mature born infants before and after vaccination schedule change— a claims database analysis. Vaccine. 2021 June;39(24):3287-3295. Li E, Mezzio DJ, Campbell D, Campbell K, Lyman GH. Primary prophylaxis with biosimilar filgrastim for patients at intermediate risk for febrile neutropenia: a cost-effectiveness analysis. JCO Oncol Pract. Published online April 1, 2021. doi:10.1200/OP.20.01047 Lokhandwala T, Coutinho AD, Bell CF. Retrospective analysis of disease severity, health care resource utilization, and costs among patients initiating belimumab for the treatment of systemic lupus erythematosus. Clin Ther. Published online July 7, 2021. https://doi.org/10.1016/j.clinthera.2021.06.009 Lokhandwala T, Yue B, Coutinho AD, Bell CF. Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus. Lupus Sci Med. 2021 Feb;8(1): e000438. doi:10.1136/lupus-2020-000438 ∗Xcenda provided medical writing and editorial assistance in development of this manuscript. Xcenda Page 2 of 86 Lodise TP, Law A, Spilsbury-Cantalupo M, Liao L, McCart M, Eaddy M. Hospital readmissions and mortality among intubated and mechanically ventilated adult subjects with pneumonia due to gram-negative bacteria. Respir Care. 2021 May;66(5):742-750. McBride A, Campbell K, Li E, Schroader B, Campbell D, Wang W. Economic and clinical outcomes of pegfilgrastim via prefilled syringe vs on-body injector: a real-world data analysis. J Manag Care Spec Pharm. 2021 April 30;1-9. [published online ahead of print]. doi.10.18553/jmcp.2021.21010 McCann W, Haas SL, Norrett K, Cameron A, Etschmaier M, Duhig A, Yu S. The peanut allergy burden study: real-world impact of peanut allergy on resource utilization and productivity. World Allergy Organ J. 2021;14(3): 100525. doi:10.1016/j.waojou.2021.100525 Pollack M, Keating K, Wissinger E, Jackson L, Sarnes E, Cuffel B. Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies. Curr Med Res Opin. 2021 Jan;37(1):59-70. Schwartz GF, Patel A, Naik R, Lunascek O, Ogbonnaya A, Campbell J. Characteristics and treatment patterns of newly diagnosed open-angle glaucoma patients in the United States: an administrative database analysis. Ophthalmol Glaucoma. 2021 Mar-Apr;4(2):117-125. Spargo A, Yost C, Squires P, Raju A, Schroader B, Brown JD. The effects of oral anticancer parity laws on out-of-pocket spending and adherence among commercially insured patients with chronic myeloid leukemia. J Manag Care Spec Pharm. 2021 May;27(5):554-564. Sewerin P, Borchert K, Meise D, Schneider M, Mahlich J. Real-world treatment persistence with biologic disease-modifying antirheumatic drugs among German patients with psoriatic arthritis—a retrospective database study. Rheumatol Ther. 2021 Mar;8(1):483-497. Trefz F, Muntau AC, Schneider KM, Altevers J, Jacob C, Braun S, Greiner W, Jha A, Jain M, Alvarez I, Lane P, Zeiss C, Rutsch F. Health economic burden of patients with phenylketonuria (PKU)—a retrospective study of German health insurance claims data. Mol Genet Metab Rep. 2021 May;27:100764. doi:10.1016/j.ymgmr.2021.100764 Velez FF, Luderer HF, Gerwien R, Parcher B, Mezzio D, Malone DC. Evaluation of the cost-utility of a prescription digital therapeutic for the treatment of opioid use disorder. Postgrad Med. 2021 May;133(4):421- 427. ∗Weidner S, Diaz M, Schaedig C, Gordan L. Observations regarding the average sales price reimbursement methodology. Evidence-Based Oncol. 2021 June;27(4):SP156-SP160. Yu JS, Carlton R, Agashivala N, Hassan T, Wykoff CC. Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis. J Manag Care Spec Pharm. 2021 June;27(6):743-752. 2020 Return to Publications Ataga KI, Gordeuk VR, Agodoa I, Colby JA, Gittings K, Allen IE. Low hemoglobin increases risk for cerebrovascular disease, kidney disease, pulmonary vasculopathy, and mortality in sickle cell disease: a systematic literature review and meta-analysis. PLoS One. 2020 Apr 3;15(4):e0229959. Borchert K, Jacob C, Wetzel N, Jӓnicke M, Eggers E, Sauer A, Marschner N, Altevers J, Mittendorf T, Greiner W. Application study of the EQ-5D-5L in oncology: linking self-reported quality of life of patients with advanced ∗Xcenda provided medical writing and editorial assistance in development of this manuscript. Xcenda Page 3 of 86 or metastatic colorectal cancer to clinical data from a German tumor registry. Health Econ Rev. 2020 Dec; 19(1):40. doi:10.1186/s13561-020-00297-6 Bruno AS, Wilson JL, Opalinska JM, Nelson JJ, Lunascek OE, Stafkey-Mailey DR, Wiley JP. Recent real-world treatment patterns and outcomes in US patients with relapsed, refractory multiple myeloma. Expert Rev Hematol. 2020 Sep;13(9):1017-1025. Canbay A, Kachru N, Haas JS, Sowa J-P, Meise D, Ozbay AB. Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2020 Oct;52(7): 1185-1194. Chari A, Romanus D, Palumbo A, Blazer M, Farrelly E, Raju A, Huang H, Richardson P. Randomized clinical trial representativeness and outcomes in real-world patients: comparison of 6 hallmark randomized clinical trials of relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):8-17.e16. Chari A, Richardson PG, Romanus D, Dimopoulos MA, Sonneveld P, Terpos E, Hajek R, Raju A, Palumbo A, Cain LE, Blazer M, Huang H, Farrelly E, Ailawadhi S. Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. Expert Rev Hematol. 2020 Mar;9:1-13. Coleman C, Salam T, Duhig A, Patel AA, Cameron A, Voelker J, Bookhart B. Impact of non-medical switching of prescription medications on health outcomes: an e-survey of high-volume Medicare and Medicaid physician providers. J Mark Access Health Policy. 2020;8(1). doi:10.1080/20016689.2020.1829883 Costa OS, Salam T, Duhig A, Patel AA, Cameron A, Voelker J, Bookhart B, Coleman CI. Specialist physician perspectives on non-medical switching of prescription medications. J Mark Access Health Policy. 2020;8(1):1-10. Dean BB, Saundankar V, Stafkey-Mailey D, Anguiano RH, Nelsen AC, Gordon K, Classi P. Medication adherence and healthcare costs among patients with pulmonary arterial hypertension treated with oral prostacyclins: a retrospective cohort study. Drugs Real World Outcomes. 2020 Sep;7(3):229-239. Haas JS, Krinke K-S, Maas C, Hardt T, Barck I, Braun S. The burden of hyperkalemia in Germany—a real world evidence study assessing the treatment and costs of hyperkalemia. BMC Nephrol. 2020 Aug;21(1):332. doi:10.1186/s12882-020-01942-2 Ho-Mahler N, Turner B, Eaddy M, Hanke ML, Nelson WW. Treatment with repository corticotropin injection in patients with rheumatoid arthritis, systemic lupus erythematosus, and dermatomyositis/ polymyositis. Open Access Rheumatol. 2020 Feb;12:21-28. Jesudian AB, Ahmad M, Bozkya D, Migliaccio-Walle K. Cost-effectiveness of rifaximin treatment in patients with hepatic encephalopathy. J Manag Care Spec Pharm. 2020 Jun;26(6):750-757. Kudrow D, Munjal S, Bensimon L, Lokhandwala T, Yue B, Coutinho AD, Silberstein SD. Treatment patterns of patients diagnosed with major headache disorders: a retrospective claims analysis. Cephalalgia Reports. 2020;3:1-12. Lin HM, Pan X, Biller A, Covery KJ, Huang H, Sugarman R, Scipione F, West H. Humanistic burden of living with anaplastic lymphoma kinase-positive non-small-cell lung cancer: findings from the ALKConnect patient insight network and research platform. Lung Cancer Manag. 2020. https://doi.org/10.2217/lmt-2020-0018 Lodise TP, Tilotson GS, Spargo A, Bozkaya D, Massey J. The role of delafloxacin in patients with community- acquired bacterial pneumonia in the outpatient setting: a budget impact model. Clin Drug Investig. 2020 Oct; 40(10):961-971.